Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries

Miura, John T.; Evans, Douglas B.; Pappas, Sam G.; Gamblin, T. Clark; Turaga, Kiran K.
December 2013
Annals of Surgical Oncology: An Oncology Journal for Surgeons;Dec2013, Vol. 20 Issue 13, p4338
Academic Journal
No abstract available.


Related Articles

  • Current Issues.  // PharmacoEconomics & Outcomes News;12/1/2007, Issue 542, p2 

    The article reports that a new section that covers principles of palliation and supportive care has been added to the National Comprehensive Cancer Network (NCCN) Pancreatic Adenocarcinoma Guidelines. According to the NCCN, the new section is an important addition, since a significant subset of...

  • Management of Pancreatic Cancer: Current Status and Future Directions. Ramesh, H. // Indian Journal of Surgery;Aug2010, Vol. 72 Issue 4, p285 

    Pancreatic ductal adenocarcinoma has a dismal prognosis, despite advances in surgery, and adjuvant therapy. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline respectability. Extended...

  • Management of pancreatic cancer: Current status and future directions. Ramesh, H. // Indian Journal of Surgery;Dec2009, Vol. 71 Issue 6, p368 

    Despite advances in surgery and adjuvant therapy pancreatic ductal adenocarcinoma has a dismal prognosis. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline resectability. Extended...

  • Does Ablation Technique Utilized in the Management of Unresectable Locally Advanced Pancreatic Adenocarcinoma? Pezzilli, Raffaele; Fabbri, Dario; Imbrogno, Andrea // Cancers;2010, Vol. 2 Issue 4, p2098 

    Radiofrequency ablation in the management of advanced pancreatic cancer should be no longer utilized in patients with locally advanced or metastatic pancreatic adenocarcinoma.

  • Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. SHAIB, WALID L.; IP, ANDREW; CARDONA, KENNETH; ALESE, OLATUNJI B.; MAITHEL, SHISHIR K.; KOOBY, DAVID; LANDRY, JEROME; EL-RAYES, BASSEL F. // Oncologist;Feb2016, Vol. 21 Issue 2, p178 

    Adenocarcinoma of the pancreas remains a highly lethal disease, with less than 5% survival at 5 years. Borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) account for approximately 30% of newly diagnosed cases of PC. The objective of BRPC...

  • Antineoplastics.  // Reactions Weekly;1/30/2016, Vol. 1586 Issue 1, p42 

    An abstract of the article "Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma," by C. Tinchon and others is presented.

  • A Systematic Review of Neoadjuvant Therapy Compared to the "Resection First" Approach for Patients with Borderline Resectable Pancreatic Adenocarcinoma. Toomey, Paul G.; Ross, Sharona; Shah, Shalin; Rosemurgy, Alexander S. // Journal of Cancer Therapy;Jan2014, Vol. 5 Issue 1, p91 

    Background: Survival for patients with pancreatic adenocarcinoma continues to be poor. Patients with pancreatic adenocarcinoma that is deemed borderline resectable have imaging that shows disease involvement of the portal vein and/or superior mesenteric vein that is amenable to reconstruction or...

  • Long Term Complete Response of Unresectable Locally Advanced Pancreatic Cancer after CCRT and Gemcitabine Chemotherapy. Jaeyun Yang; Taekyu Lim; Taegyoon Kim; Seungmoon Han; Sanghee Lee; Huiseo Kim; Jiwon Lee; Seongyeong Ahn // Korean Journal of Pancreas & Biliary Tract;Oct2016, Vol. 21 Issue 4, p209 

    Locally advanced or metastatic disease accounts for two thirds of total patients with pancreatic cancer. Patients with pancreatic cancer are assessed as resectable, potentially resectable (borderline) or unresectable according to pre-operative examinations. The chances of resectability may be...

  • Cetuximab did not improve outcome in advanced pancreatic cancer.  // Hem/Onc Today;8/25/2010, Vol. 11 Issue 16, p30 

    This article discusses a study by Philip A. Phillip of the Karmanos Cancer Institute and colleagues which compared the efficacy of gemcitabine with gemcitabine plus cetuximab in improving mean survival rate among patients with advanced pancreatic adenocarcinoma.

  • Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Tempero, Margaret // Journal of Oncology Practice;Jan2016, Vol. 12 Issue 1, p29 

    The article presents a commentary on "Clinical insights into the biology and treatment opportunities in pancreatic cancer," by N.B. Mettu and J.L. Abbruzzese in the January 2016 issue, on pancreatic adenocarcinoma. Topics discussed include funding of seven U01 grants by National Institute of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics